ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0419

Efficacy of Upadacitinib in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Objective Signs of Inflammation at Baseline

Walter P Maksymowych1, Xenofon Baraliakos2, Atul Deodhar3, Denis Poddubnyy4, Fabiana Ganz5, Tianming Gao6, Jayne Stigler6, Anna K Shmagel6, Peter Wung6 and Filip Van den bosch7, 1Department of Medicine, University of Alberta, Edmonton, AB, Canada, 2Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 3Oregon Health & Science University, Portland, OR, USA, Portland, OR, 4Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 5AbbVie, Inc., Luzern, Switzerland, 6AbbVie, Inc., North Chicago, IL, 7Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium

Meeting: ACR Convergence 2022

Keywords: C-reactive protein (CRP), clinical trial, Inflammation, Magnetic resonance imaging (MRI), spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Spondyloarthritis Including PsA – Treatment Poster I: AxSpA

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: The Phase 3 SELECT-AXIS 2 trial (NCT04169373) assessed the efficacy and safety of upadacitinib (UPA) in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Here, we present a subgroup analysis of the SELECT-AXIS 2 efficacy data stratified by elevated high-sensitivity CRP (hsCRP) and positivity for MRI inflammation in the sacroiliac (SI) joints at screening.

Methods: In SELECT-AXIS 2,1 patients aged ≥18 years with a clinical diagnosis of nr-axSpA, meeting the 2009 Assessment of Spondyloarthritis international Society (ASAS) classification criteria for axSpA, but not the radiologic criterion of the modified New York criteria for AS, and with objective signs of active inflammation on MRI per the ASAS definition (assessed by two primary readers and an adjudicator) and/or hsCRP exceeding the upper limit of normal (ULN, 2.87 mg/L) at screening, were randomized 1:1 to UPA 15 mg once daily or placebo (PBO). The primary endpoint, measured at Week (Wk) 14, was the ASAS40 response. Additional endpoints included Ankylosing Spondylitis Disease Activity Score (ASDAS) Low Disease Activity (LDA) with a score ≤2.1, change from baseline (BL) in MRI Spondyloarthritis Research Consortium of Canada (SPARCC) score (SI joints), BASFI, and patients’ assessments of total back pain, all at Wk 14. Prespecified (ASAS40 response) and post hoc (all other endpoints) subgroup analyses were carried out by inflammatory status, with hsCRP ( >ULN vs ≤ULN) and MRI SI joint inflammation status (positive vs negative) at screening as stratification factors. A separate subgroup analysis by BL hsCRP status alone is also presented. Non-response imputation (NRI) with multiple imputation (MI), incorporating MI to handle missing data due to COVID-19, was used for binary outcomes. Mixed model for repeated measures based on as-observed (AO) data was used for continuous outcomes except MRI SPARCC score. Analysis of covariance based on AO data was used for MRI SPARCC score.

Results: Of 312 patients included in the analysis, 176 (56%) had hsCRP >ULN and were MRI negative (MRI−), 73 (23%) had hsCRP >ULN and were MRI positive (MRI+), and 63 (20%) had hsCRP ≤ULN and were MRI+. BL demographics and disease characteristics were generally similar across subgroups, although the hsCRP >ULN and MRI+ subgroup had a higher frequency of HLA-B27-positive patients and a lower rate of prior biologic DMARD (bDMARD) exposure than the other subgroups (Table 1). UPA was associated with increased ASAS40 and ASDAS LDA rates, and greater reductions in MRI SPARCC score, BASFI, and total back pain from BL, vs PBO across all subgroups at Wk 14 (Figure 1). The treatment difference between UPA and PBO was greatest in the hsCRP >ULN and MRI+ group for all endpoints. When considering BL hsCRP alone, the treatment difference was greater in the hsCRP >ULN group vs the hsCRP ≤ULN subgroup for all endpoints except change from BL in MRI SPARCC score (SI joints) (Figure 2).

Conclusion: In SELECT-AXIS 2, UPA improved outcomes vs PBO in patients with nr-axSpA across all BL inflammation subgroups; the greatest benefit was observed in patients with both elevated CRP levels and evidence of inflammation on MRI at screening.

Reference 1. Deodhar A, et al. Ann Rheum Dis 2022;81(Suppl 1):9. Abstract OP0016

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: W. Maksymowych, AbbVie, Boehringer-Ingelheim, Celgene, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, UCB, CARE Arthritis Limited; X. Baraliakos, AbbVie, Lilly, Galapagos, MSD, Novartis, Pfizer, UCB, Bristol-Myers Squibb, Janssen, Roche, Sandoz, Sanofi; A. Deodhar, AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, Novartis, Pfizer Inc, UCB Pharma, Aurinia, Moonlake; D. Poddubnyy, AbbVie, Biocad, Bristol-Myers Squibb, Eli Lilly, Gilead, GlaxoSmithKline, MSD, Moonlake, Novartis, Pfizer, Samsung-Bioepis, UCB; F. Ganz, AbbVie; T. Gao, AbbVie; J. Stigler, AbbVie; A. Shmagel, AbbVie; P. Wung, AbbVie; F. Van den bosch, AbbVie, Lilly, Galapagos, Janssen, Merck, Novartis, Pfizer, UCB, Amgen, Bristol-Myers Squibb(BMS), Celgene.

To cite this abstract in AMA style:

Maksymowych W, Baraliakos X, Deodhar A, Poddubnyy D, Ganz F, Gao T, Stigler J, Shmagel A, Wung P, Van den bosch F. Efficacy of Upadacitinib in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Objective Signs of Inflammation at Baseline [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/efficacy-of-upadacitinib-in-patients-with-non-radiographic-axial-spondyloarthritis-stratified-by-objective-signs-of-inflammation-at-baseline/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-upadacitinib-in-patients-with-non-radiographic-axial-spondyloarthritis-stratified-by-objective-signs-of-inflammation-at-baseline/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology